Valuation: AstraZeneca PLC

Market Cap 267B 234B 218B 201B 376B 25,509B 383B 2,589B 1,013B 12,651B 1,002B 981B 43,709B P/E 2026 *
22x
P/E 2027 * 19.2x
Enterprise Value 287B 252B 235B 216B 404B 27,425B 411B 2,783B 1,089B 13,601B 1,078B 1,054B 46,992B EV / Sales 2026 *
4.54x
EV / Sales 2027 * 4.18x
Free-Float
96.63%
Yield 2026 *
1.93%
Yield 2027 * 2.05%
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 267B
+1.93%+3.85%+51.05%+166.24% 1,089B
+0.29%+6.43%+60.47%+52.87% 643B
+2.45%+2.77%+39.61%+74.48% 465B
-0.65%+9.99%+40.89%+35.11% 359B
-0.34%+3.51%+36.97%+42.46% 303B
-0.30%+4.69%-3.57%-38.75% 226B
+4.48%+7.33%+30.47%+66.31% 212B
+2.91%+3.10%+18.84%+74.76% 167B
+2.35%+1.24%+3.87%-30.00% 144B
Average -0.05%+4.64%+30.95%+49.28% 400.89B
Weighted average by Cap. -0.02%+5.04%+41.05%+79.97%

Financials

2026 *2027 *
Net sales 63.29B 55.54B 51.72B 47.57B 89.18B 6,046B 90.71B 614B 240B 2,999B 238B 232B 10,360B 66.84B 58.66B 54.62B 50.24B 94.18B 6,385B 95.79B 648B 254B 3,167B 251B 246B 10,941B
Net income 12.08B 10.61B 9.88B 9.08B 17.03B 1,155B 17.32B 117B 45.86B 573B 45.37B 44.39B 1,978B 13.71B 12.03B 11.2B 10.31B 19.32B 1,310B 19.65B 133B 52.03B 650B 51.47B 50.36B 2,244B
Net Debt 20.05B 17.6B 16.39B 15.07B 28.26B 1,916B 28.74B 194B 76.1B 950B 75.29B 73.66B 3,283B 12.56B 11.02B 10.27B 9.44B 17.7B 1,200B 18B 122B 47.67B 595B 47.16B 46.14B 2,056B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
172.15USD
Average target price
211.36USD
Spread / Average Target
+22.78%

Quarterly revenue - Rate of surprise